Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadia Harbeck

Showing results (41-50 of 585) with videos related to

Pageof 59
Sort By:
Therapeutic Advances in Medical Oncology|September 15, 2022
Clinical validity and clinical utility of Ki67 in early breast cancerHans Kreipe, Nadia Harbeck, Matthias Christgen
Breast Care (Basel, Switzerland)|May 20, 2021
Fifteen Years of <i>Breast Care</i>Christoph Thomssen, Nadia Harbeck, Michael Gnant
Breast Care (Basel, Switzerland)|August 2, 2013
AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012Anton Scharl, Christoph Thomssen, Nadia Harbeck
Breast Care (Basel, Switzerland)|September 4, 2013
St. Gallen 2013: brief preliminary summary of the consensus discussionNadia Harbeck, Christoph Thomssen, Michael Gnant
Breast Care (Basel, Switzerland)|June 1, 2017
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer TreatmentMichael Gnant, Nadia Harbeck, Christoph Thomssen
Breast Care (Basel, Switzerland)|July 22, 2015
St. Gallen/Vienna 2015: A Brief Summary of the Consensus DiscussionMichael Gnant, Christoph Thomssen, Nadia Harbeck
Critical Reviews in Oncology/Hematology|April 30, 2010
Bisphosphonates in adjuvant treatment of early breast cancer, Nadia Harbeck, Gunter von Minckwitz, et al.
Expert Opinion on Investigational Drugs|May 30, 2014
Afatinib in the treatment of breast cancerSara A Hurvitz, Rebecca Shatsky, Nadia Harbeck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combinationNadia Harbeck, Ronald E Kates, Manfred Schmitt
Future Oncology (London, England)|December 17, 2013
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neckNadia Harbeck, Flavio Solca, Thomas C Gauler
Pageof 59

Showing results (41-50 of 585) with videos related to

Sort By:
Pageof 59
Therapeutic Advances in Medical Oncology|September 15, 2022
Clinical validity and clinical utility of Ki67 in early breast cancerHans Kreipe, Nadia Harbeck, Matthias Christgen
Breast Care (Basel, Switzerland)|May 20, 2021
Fifteen Years of <i>Breast Care</i>Christoph Thomssen, Nadia Harbeck, Michael Gnant
Breast Care (Basel, Switzerland)|August 2, 2013
AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012Anton Scharl, Christoph Thomssen, Nadia Harbeck
Breast Care (Basel, Switzerland)|September 4, 2013
St. Gallen 2013: brief preliminary summary of the consensus discussionNadia Harbeck, Christoph Thomssen, Michael Gnant
Breast Care (Basel, Switzerland)|June 1, 2017
St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer TreatmentMichael Gnant, Nadia Harbeck, Christoph Thomssen
Breast Care (Basel, Switzerland)|July 22, 2015
St. Gallen/Vienna 2015: A Brief Summary of the Consensus DiscussionMichael Gnant, Christoph Thomssen, Nadia Harbeck
Critical Reviews in Oncology/Hematology|April 30, 2010
Bisphosphonates in adjuvant treatment of early breast cancer, Nadia Harbeck, Gunter von Minckwitz, et al.
Expert Opinion on Investigational Drugs|May 30, 2014
Afatinib in the treatment of breast cancerSara A Hurvitz, Rebecca Shatsky, Nadia Harbeck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combinationNadia Harbeck, Ronald E Kates, Manfred Schmitt
Future Oncology (London, England)|December 17, 2013
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neckNadia Harbeck, Flavio Solca, Thomas C Gauler
Pageof 59